MSDC-0602K (Azemiglitazone potassium) (Azemiglitazone potassium) is a PPARγ-sparing thiazolidinedione (Ps-TZD) compound that binds to PPARγ with an IC50 of 18.25 μM. It also modulates the mitochondrial pyruvate carrier (MPC). This compound, MSDC-0602K, has potential applications in researching fatty liver conditions, including dysfunctional lipid metabolism, inflammation, and insulin resistance. MSDC-0602K acts as an insulin sensitizer, improving insulinemia and fatty liver disease in mice both individually and in combination with Liraglutide.

PPARγ:18.25 μM

Diabetic db/db and MS-NASH mice are treated with MSDC-0602K via oral gavage, Liraglutide via s.c. injection, or a combination of MSDC-0602K + Liraglutide. This combination treatment may be an effective therapeutic strategy for diabetes and non-alcoholic steatohepatitis. Animal Model: Five-week-old male db/db mice on C57BL/6J background and age/sex-matched db/+ control mice [1]. Dosage: 30 mg/kg MSDC-0602K and 0.2 mg/kg Liraglutide. Administration: MSDC-0602K gavage daily, Liraglutide s.c. every other day, or combined MSDC-0602K + Liraglutide. Result: MSDC-0602K alone corrected glycemia and reduced insulinemia, while the combination with Liraglutide significantly improved glucose tolerance and liver histology[1].